Eileen McMahon

Partner, Chair of Intellectual Property and Food and Drug Regulatory Practices

Torys LLP

Eileen’s market-leading experience, practical advice and industry insight in intellectual property and regulatory law make her a go-to advisor for life sciences clients.

Chair of Torys’ Intellectual Property and Food and Drug Regulatory practices, Eileen is one of a handful of Canadian lawyers who advise on regulatory clearance and intellectual property protection of products. Across the life science sector—including medicines, medical devices, medtech -—Eileen helps clients identify IP and regulatory assets, obtain and maintain market exclusivity, exploit IP assets and enforce their IP rights.

Eileen has particular expertise in the realm of pricing of pharmaceuticals, including the pricing of patented medicines and the jurisdiction of the PMPRB.

Eileen is a registered patent and trademark agent in the United States and Canada and is adroit at navigating the issues at play in cross-border matters. She is also a Certified Licensing Professional of the Licensing Executive Society (LES), United States and Canada. Eileen has received many accolades, including the LMG Life Sciences Hall of Fame Award; Chambers Canada Star Individual recognition in life sciences: regulatory/compliance (the only lawyer ranked in the highest category in Canada in life sciences); and Managing IP’s IP Stars recognition in patent and trademark, as well as Top 250 Women in IP.

All Sessions by Eileen McMahon

Printer Friendly See Full Agenda

Agenda: Day 1 Oct 5, 2020

11:30 am

11:30 am

PMPRB ’22 GUIDELINES – WHAT DO WE KNOW SO FAR? SPECIAL Q&A

The PMPRB released its revised draft Guidelines on October 6th, making big news for the industry! Gain a better understanding of the details to prepare your senior management team both in Canada and internationally. Take away new perspectives and deepen your knowledge on:

  • How the guidelines have been ‘updated’ given previous litigation
  • Is what was formerly a ‘competition bureau’ approach applicable to drug pricing?
  • What does TRUE access mean?
  • Which arguments are acceptable in the face of future manufacturer investigations?

Set yourself up for success with answers to your toughest PMPRB questions.

Agenda: Day 2 Oct 6, 2020